Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

308 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Incretins, insulin secretion and Type 2 diabetes mellitus.
Vilsbøll T, Holst JJ. Vilsbøll T, et al. Diabetologia. 2004 Mar;47(3):357-366. doi: 10.1007/s00125-004-1342-6. Epub 2004 Feb 13. Diabetologia. 2004. PMID: 14968296 Review.
Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ. Vilsbøll T, et al. Diabetes Care. 2000 Jun;23(6):807-12. doi: 10.2337/diacare.23.6.807. Diabetes Care. 2000. PMID: 10841001
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.
Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Vilsbøll T, et al. Diabetes. 2001 Mar;50(3):609-13. doi: 10.2337/diabetes.50.3.609. Diabetes. 2001. PMID: 11246881
No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.
Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Vilsbøll T, et al. Diabet Med. 2001 Feb;18(2):144-9. doi: 10.1046/j.1464-5491.2001.00424.x. Diabet Med. 2001. PMID: 11251679
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Vilsbøll T, et al. Diabetologia. 2002 Aug;45(8):1111-9. doi: 10.1007/s00125-002-0878-6. Epub 2002 Jul 4. Diabetologia. 2002. PMID: 12189441
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.
Vilsbøll T, Agersø H, Krarup T, Holst JJ. Vilsbøll T, et al. J Clin Endocrinol Metab. 2003 Jan;88(1):220-4. doi: 10.1210/jc.2002-021053. J Clin Endocrinol Metab. 2003. PMID: 12519856
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ. Vilsbøll T, et al. J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13. doi: 10.1210/jc.2002-021873. J Clin Endocrinol Metab. 2003. PMID: 12788877
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Vilsbøll T, et al. Regul Pept. 2003 Jul 15;114(2-3):115-21. doi: 10.1016/s0167-0115(03)00111-3. Regul Pept. 2003. PMID: 12832099
No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.
Knop FK, Vilsbøll T, Larsen S, Madsbad S, Holst JJ, Krarup T. Knop FK, et al. Among authors: vilsboll t. Diabetes Care. 2003 Sep;26(9):2581-7. doi: 10.2337/diacare.26.9.2581. Diabetes Care. 2003. PMID: 12941722 Clinical Trial.
The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ. Vilsbøll T, et al. J Clin Endocrinol Metab. 2003 Oct;88(10):4897-903. doi: 10.1210/jc.2003-030738. J Clin Endocrinol Metab. 2003. PMID: 14557471 Clinical Trial.
308 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback